enrgy: zenocutuzumab in nrg1 fusion-positive nsclc
Published 9 months ago • 98 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:29
enrgy: zenocutuzumab in nrg1 fusion–positive tumors
-
0:46
enrgy: zenocutuzumab in nrg1 fusion-positive pancreatic ductal adenocarcinoma
-
0:34
rational for her3-targeting in nrg1 fusion-positive nsclc
-
4:03
phase i/ii trial of zenocutuzumab for tumors with nrg1 fusions
-
12:49
nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
-
2:09
dr. tolba on targeting nrg1 fusions in nsclc
-
0:58
dr. shum on mechanisms of resistance in oncogene-driven nsclc
-
9:16
behind the mystery: nrg1 fusions
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
2:45
dr. liu on nrg1 fusions in oncology
-
1:33
real-world experience of impower150 regimen for egfr nsclc
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
0:40
evaluating next steps for entrectinib in ros1-positive nsclc
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
1:30
interpreting the role of ramucirumab plus erlotinib combination in egfr nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
2:31
dr. duruisseaux on the incidence of nrg1 fusions in solid tumors
-
4:27
entrectinib: a review in ntrk solid tumours and ros1 nsclc